Aerovate Therapeutics Net Income 2020-2025 | JBIO
Aerovate Therapeutics net income from 2020 to 2025. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Aerovate Therapeutics Annual Net Income
(Millions of US $) |
| 2024 |
$-70 |
| 2023 |
$-76 |
| 2022 |
$-52 |
| 2021 |
$-23 |
| 2020 |
$-10 |
| 2019 |
$-3 |
Aerovate Therapeutics Quarterly Net Income
(Millions of US $) |
| 2025-03-31 |
$-3 |
| 2024-12-31 |
$-5 |
| 2024-09-30 |
$-16 |
| 2024-06-30 |
$-25 |
| 2024-03-31 |
$-23 |
| 2023-12-31 |
$-20 |
| 2023-09-30 |
$-20 |
| 2023-06-30 |
$-19 |
| 2023-03-31 |
$-17 |
| 2022-12-31 |
$-15 |
| 2022-09-30 |
$-14 |
| 2022-06-30 |
$-12 |
| 2022-03-31 |
$-11 |
| 2021-12-31 |
$-8 |
| 2021-09-30 |
$-6 |
| 2021-06-30 |
$-6 |
| 2021-03-31 |
$-3 |
| 2020-12-31 |
$-4 |
| 2020-09-30 |
$-2 |
| 2020-06-30 |
$-2 |
| 2020-03-31 |
$-1 |
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.008B |
$0.000B |
|
Aerovate Therapeutics Inc. is a clinical stage biopharmaceutical company. It focused on developing drugs for cardiopulmonary disease. The company's product pipeline consist AV-101. Aerovate Therapeutics Inc. is based in BOSTON.
|
